RA Capital Management EVMN Position
Active3-Fund ConvergenceRA Capital Management initiated a new position in Evommune, Inc. (EVMN) in Q4 2025, holding $59.2M worth of shares across 3,458,770 shares.
EVMN is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for EVO756 in 45 days (May 31, 2026), making the timing of RA Capital's position particularly relevant.
Short interest stands at 10.1% of float with 10.5 days to cover, indicating significant bearish positioning against RA Capital's long thesis.
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Full company profile →Short Interest
10.1%
10.5 days to cover
Frequently Asked Questions
Does RA Capital Management own EVMN?
Yes. As of Q4 2025, RA Capital Management holds 3,458,770 shares of Evommune, Inc. (EVMN) valued at $59.2M. This data comes from their SEC 13F filing.
How many hedge funds own EVMN?
3 specialist biotech hedge funds currently hold EVMN, including RTW Investments, Eventide Asset Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy EVMN?
RA Capital Management's position in EVMN was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's EVMN position increasing or decreasing?
RA Capital Management initiated a new position in EVMN in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
EVMNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →